Patents by Inventor Marianne Dewerchin
Marianne Dewerchin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230109362Abstract: The present invention relates to compositions and methods for monitoring viral synthesis inside a host cell. Compositions of the invention act as biosensors and can detect virus synthesized in a host cell in situ.Type: ApplicationFiled: May 12, 2021Publication date: April 6, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Marianne DEWERCHIN
-
Patent number: 10947280Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: GrantFiled: June 29, 2020Date of Patent: March 16, 2021Assignee: GlaxoSmithKline Biologicals SAInventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
-
Publication number: 20200325184Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: ApplicationFiled: June 29, 2020Publication date: October 15, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Normand BLAIS, Cindy CASTADO, Patrick CHOMEZ, Marianne DEWERCHIN
-
Patent number: 10745449Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: GrantFiled: June 29, 2018Date of Patent: August 18, 2020Assignee: GlaxoSmithKlineInventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
-
Publication number: 20190322708Abstract: Methods for the production of a bacterial toxin such as diphtheria toxin, and methods for producing conjugates of a bacterial toxins, are provided.Type: ApplicationFiled: July 11, 2019Publication date: October 24, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
-
Publication number: 20180354996Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: ApplicationFiled: June 29, 2018Publication date: December 13, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
-
Publication number: 20180258146Abstract: Methods for producing a conjugate of a bacterial toxin, including diphtheria toxin or CRM197, are provided.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Normand BLAIS, Philippe Marc Helene DEHOTTAY, Marianne DEWERCHIN, Philippe GOFFIN, Denis MARTIN
-
Patent number: 10040832Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: GrantFiled: February 20, 2015Date of Patent: August 7, 2018Assignee: GlaxoSmithKline Biologicals SAInventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
-
Patent number: 9994622Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.Type: GrantFiled: July 14, 2016Date of Patent: June 12, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
-
Publication number: 20170137475Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.Type: ApplicationFiled: July 14, 2016Publication date: May 18, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Normand BLAIS, Philippe Marc Helene DEHOTTAY, Marianne DEWERCHIN, Philippe GOFFIN, Denis MARTIN
-
Publication number: 20170008932Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: ApplicationFiled: February 20, 2015Publication date: January 12, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Normand BLAIS, Cindy CASTADO, Patrick CHOMEZ, Marianne DEWERCHIN
-
Patent number: 9422345Abstract: Polynucleotides are provided herein.Type: GrantFiled: October 7, 2010Date of Patent: August 23, 2016Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
-
Publication number: 20120289688Abstract: Polynucleotides are provided herein.Type: ApplicationFiled: October 7, 2010Publication date: November 15, 2012Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
-
Publication number: 20090035330Abstract: The present invention provides a vaccine composition comprising the B-subunit of E. coli heat labile toxin or a derivative thereof with equal or greater than 90% homology complexed with an antigen and an adjuvant.Type: ApplicationFiled: May 18, 2006Publication date: February 5, 2009Inventor: Marianne Dewerchin